Report #2878129

Received Dec 16, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: MO
Recovered: Unknown
Vaccinated: Oct 14, 2025
Onset: Nov 11, 2025
Days to onset: 28
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	946904	IM

Symptoms (1)

Interchange of vaccine products

Symptom narrative

Received First Dose of HEPLISAV-B on 10/14/25, and Second Dose of Engerix-B on 11/11/25; Initial report received on 11-Nov-2025. A pharmacist reported that a male received HEPLISAV-B (hepatitis B vaccine) for the first dose of hepatitis B immunization and ENGERIX-B for the second dose of hepatitis B immunization. No medical history or concomitant medications were reported. On 14-Oct-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 946904, expiration date 17-Oct-2027, and NDC number 43528-003-05; site not provided)] intramuscularly. On 11-Nov-2025, 29 days after receiving HEPLISAV-B, the patient received dose 2 of a hepatitis B vaccine [ENGERIX-B (lot number not provided)]. The patient had no other side effects. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Engerix b